JOHNSON & JOHNSON STOCK OVERVIEW

SNAPSHOT

Ticker	JNJ	Market Cap	$582B
Sector	Biopharmaceuticals	P/E	21.87
52 Week High-Low	$141.50 - $251.71	3 Year Beta	0.46
CEO	Joaquin Duato	Target Price	$215.29

BUSINESS MODEL

Products

Johnson & Johnson develops and markets a broad portfolio of healthcare products through two primary business segments: Innovative Medicine and MedTech. The Innovative Medicine segment focuses on the research, development, and commercialization of prescription pharmaceuticals across major therapeutic areas such as oncology, immunology, neuroscience, infectious diseases, and cardiovascular and metabolic disorders. These medicines are designed to treat complex diseases and are typically prescribed by healthcare professionals and distributed through hospitals, pharmacies, and medical distributors. The MedTech segment produces medical devices and technologies used in surgery, cardiovascular care, orthopaedics, and vision correction. Its products include surgical instruments, joint reconstruction implants, electrophysiology technologies, stroke treatment devices, and vision care products such as contact lenses and intraocular lenses used in cataract procedures.

Customer Base

Johnson & Johnson serves a global customer base that includes hospitals, healthcare systems, pharmacies, medical distributors, and government healthcare programs. Pharmaceutical products are primarily purchased by wholesalers and healthcare providers that distribute prescription medicines to patients through pharmacies and hospitals. MedTech products are sold directly to hospitals, surgical centers, and physicians who use these devices in medical procedures. Vision care products are also distributed through eye care professionals such as optometrists and ophthalmologists. Through these channels, the company supplies treatments and medical technologies to healthcare providers and patients across many countries and healthcare systems.

Pricing Method

Johnson & Johnson’s pricing is influenced by healthcare market conditions, regulatory frameworks, and reimbursement systems. Pharmaceutical pricing depends on factors such as research and development costs, therapeutic effectiveness, competition from other drugs, and negotiations with government programs, insurers, and pharmacy benefit managers. Pricing for medical devices and surgical technologies is influenced by product innovation, clinical performance, and demand from hospitals and healthcare systems. Because healthcare spending is often reimbursed by insurers or government programs, pricing decisions are also affected by reimbursement policies and cost containment efforts within the healthcare industry.

Supply Chain

Johnson & Johnson operates a global manufacturing and distribution network that supports the production and delivery of pharmaceuticals and medical technologies. The company manages research and development facilities, manufacturing plants, and logistics infrastructure that supply products to healthcare providers around the world. Pharmaceutical products are manufactured using specialized chemical and biological processes and then distributed through wholesalers, pharmacies, and hospitals. Medical devices are produced in dedicated manufacturing facilities and delivered to hospitals, surgical centers, and medical professionals. This integrated supply chain allows the company to support global healthcare demand while maintaining product quality and regulatory compliance.

Sales Channels

Johnson & Johnson distributes its products through multiple sales channels tailored to healthcare markets. Pharmaceutical products are sold through wholesalers, distributors, hospitals, and pharmacies that provide prescription medicines to patients. Medical devices and surgical technologies are marketed directly to hospitals, surgeons, and healthcare systems through specialized sales teams and distributor networks. Vision care products are distributed through optical retailers and eye care professionals. These sales channels allow the company to reach healthcare providers, medical institutions, and patients across global healthcare markets.

INDUSTRY ANALYSIS: PORTER'S 5 FORCES

Threat of New Entrants — Low

The threat of new entrants in the global healthcare and pharmaceutical industry is low due to significant regulatory, financial, and technological barriers. Developing new pharmaceutical drugs or medical technologies requires substantial investment in research and development, clinical trials, regulatory approval, and manufacturing infrastructure. These processes can take many years and cost billions of dollars before a product reaches the market. In addition, companies must obtain approvals from regulatory authorities such as the FDA and other global health regulators, which creates additional complexity for new firms. Johnson & Johnson’s established research capabilities, global distribution networks, patent portfolio, and long-standing relationships with healthcare providers further strengthen its competitive position and make it difficult for new competitors to enter the industry at scale.

Bargaining Power of Buyers — Moderate

Buyers in the healthcare industry include hospitals, healthcare systems, pharmacies, government healthcare programs, and insurance providers. Large buyers often purchase medicines and medical devices in significant volumes, giving them some negotiating power over pricing and supply contracts. Government healthcare systems and insurance companies also influence pricing through reimbursement policies and cost containment measures. However, buyer power is limited by the specialized nature of many pharmaceutical treatments and medical technologies. When a product offers strong clinical effectiveness or addresses a critical medical need, healthcare providers may have limited alternatives, reducing their ability to switch suppliers easily.

Bargaining Power of Suppliers — Moderate

Suppliers in the pharmaceutical and medical technology industries provide raw materials, specialized chemicals, biological components, manufacturing equipment, and technology used in product development and production. Some inputs, particularly biologic materials or specialized medical components, may be sourced from a limited number of qualified suppliers. This can increase supplier influence in certain parts of the supply chain. However, large companies such as Johnson & Johnson typically maintain diversified supplier networks and long-term supply agreements that help reduce dependency on any single supplier and limit overall supplier bargaining power.

Threat of Substitutes - Moderate

The threat of substitutes in the healthcare industry exists through alternative treatments, competing pharmaceuticals, generic drugs, biosimilars, and different medical procedures that address similar conditions. Once patents expire, generic or biosimilar competitors can enter the market and provide lower-cost alternatives to branded drugs. In addition, new medical technologies or treatment methods developed by competitors can replace existing therapies. However, substitutes are often limited when a drug or device offers unique clinical benefits, strong safety profiles, or is supported by extensive medical evidence, which helps protect demand for established products.

 Competitive Rivalry — High

Competitive rivalry in the pharmaceutical and medical technology industries is intense due to the presence of many large global healthcare companies competing across multiple therapeutic and device markets. Companies invest heavily in research and development to create innovative treatments and technologies that can gain regulatory approval and capture market share. Competition also occurs through pricing strategies, product performance, patent protection, marketing, and partnerships with healthcare providers. Because successful products can generate significant revenue, firms continuously compete to develop new therapies and medical technologies that can differentiate them from competitors and maintain long-term market leadership.

VALUATION: DISCOUNTED CASH FLOW

WACC

INVESTMENT RISKS

Systematic Risk

Market Risk: Johnson & Johnson’s market risk is tied to changes in demand, pricing pressure in pharmaceuticals, and competition from generics, biosimilars, and competing medical technologies. Although the company maintains strong profitability, margins fluctuate with industry conditions. Gross margin remained high at 67.97 percent in 2025, but operating margin has varied over time, falling to 23.52 percent in 2024 before recovering to 27.21 percent in 2025. Valuation metrics also reflect market expectations and sensitivity to earnings performance. The price to earnings ratio declined to 18.80 in 2025 from 25.02 in 2024, and enterprise value to EBITDA increased to 15.92, indicating that investor sentiment and valuation multiples can change depending on growth expectations and competitive developments in the healthcare sector.

Geopolitical Risk: Johnson & Johnson operates globally, which exposes the company to risks related to international economic conditions, currency movements, trade policy, and geopolitical tensions. Foreign exchange fluctuations can affect reported earnings and cash flows because a large portion of revenue is generated outside the United States. Global disruptions may also affect supply chains and operating efficiency. Operational metrics such as asset turnover have remained relatively stable at about 0.50 in 2025, but geopolitical disruptions could reduce efficiency by slowing production, increasing costs, or affecting the movement of products across international markets.

Unsystematic Risk

Business Risk: Business risk for Johnson & Johnson is primarily related to product development, patent protection, manufacturing continuity, and competition in pharmaceuticals and medical devices. The company’s profitability depends on its ability to develop new treatments, maintain intellectual property protection, and successfully commercialize products. Historical operating performance shows fluctuations that reflect these risks. Net margin declined from 22.27 percent in 2021 to 15.65 percent in 2023 before rising sharply to 28.46 percent in 2025. Return on invested capital also moved significantly, rising to 23.75 percent in 2025 from 13.29 percent in 2023, showing how earnings can change depending on product cycles and operational performance.

Financial Risk: Johnson & Johnson uses moderate financial leverage, which introduces some exposure to changes in interest rates and capital structure management. Debt levels remain manageable relative to earnings. Total debt to EBITDA was 1.45 in 2025, while net debt to EBITDA was 0.84, indicating that the company’s operating earnings comfortably support its debt obligations. Interest coverage remains strong as well, with EBIT covering interest expense 16.16 times and EBITDA covering interest expense 20.89 times in 2025. However, leverage has gradually increased over time, with total debt to equity rising to 60.50 percent and total debt to total assets reaching 24.76 percent in 2025.

Liquidity Risk: Johnson & Johnson’s liquidity ratios have declined over the past several years. The current ratio decreased to 1.03 in 2025 from 2.47 in 2016, while the quick ratio fell to 0.77 and the cash ratio declined to 0.37. These figures indicate that the company relies more heavily on ongoing cash flow rather than cash reserves to meet short term liabilities. Cash flow remains strong, with cash flow from operations equal to 45.32 percent of current liabilities, but reduced liquidity ratios suggest less balance sheet flexibility compared with earlier years.

Regulatory Risk: Johnson & Johnson operates in heavily regulated industries where government oversight can influence product approval, pricing, manufacturing standards, and market access. Regulatory decisions can delay product launches, impose compliance costs, or affect pricing through reimbursement policies and government healthcare programs. Changes in regulation may also influence profitability and operational performance. Variations in pretax margin illustrate how regulatory and industry factors can influence earnings, with pretax margin falling to 17.69 percent in 2023 before increasing to 34.59 percent in 2025. Because pharmaceutical and medical technology companies must comply with extensive global regulatory requirements, regulatory developments can significantly affect revenue growth and operating performance.

MANAGEMENT

Joaquin Duato

Chairman & Chief Executive Officer

Joaquin has served as Chairman and Chief Executive Officer of Johnson & Johnson and has been with the company since 1989. He previously held leadership roles across the company’s pharmaceutical and global operations businesses, including serving as President of Janssen Global Services. Joaquin has also served as an Independent Director at Hess Corp. and has been involved with organizations including the Pharmaceutical Research & Manufacturers of America, Save the Children Federation, the United States Fund for UNICEF, the CEO Roundtable on Cancer, and the U.S.–Spain Council. He holds a degree from Thunderbird School of Global Management and an MBA from Escuela Superior de Administración y Dirección de Empresas.

__________________________________________________________________________________

Joseph J. Wolk, CPA

Chief Financial Officer & Executive Vice President

Joseph has served as Chief Financial Officer and Executive Vice President since 2018 and joined the company in 1998. He previously served as Vice President and Chief Financial Officer of Janssen Pharmaceuticals from 2014 to 2016 and was a Director at Kenvue from 2023 to 2024. Joseph is a Trustee at St. Joseph’s University and a member of Stanford University School of Medicine’s Board of Advisors, the CNBC Global CFO Council, and the Wall Street Journal CFO Network. He completed his undergraduate studies at St. Joseph’s University and later graduated from Temple University Beasley School of Law.

__________________________________________________________________________________

Penny M. Heaton, MD

Chief Medical Officer

Penny has served as Chief Medical Officer of Johnson & Johnson since 2024. She previously worked at Merck & Co., Inc., where she held several leadership roles including Director of Vaccines Clinical Research from 1999 to 2006. Penny later served as Chief Medical Officer at Novavax from 2006 to 2009 and as Medical Officer at the Centers for Disease Control and Prevention. She received her undergraduate degree from the University of Louisville.

__________________________________________________________________________________

James D. Swanson

Chief Information Officer & Executive Vice President

James has served as Chief Information Officer and Executive Vice President since 2022. He previously held senior technology leadership roles at Monsanto Co., including Director and Chief Information Officer, and also served as Vice President of Information Technology at Merck & Co., Inc. James later worked at Bayer CropScience as Chief Information Officer before joining Johnson & Johnson’s pharmaceutical group in 2019 as Chief Information Officer and Vice President. He earned his undergraduate and graduate degrees from Drexel University.

__________________________________________________________________________________

Kathryn E. Wengel

Chief Technical Operations & Risk Officer

Kathryn has served as Chief Technical Operations and Risk Officer since 2023 and has been with Johnson & Johnson since 1988. She previously held leadership roles across global supply chain, manufacturing, and operational strategy within the company. Kathryn also serves as Chairman of the National Association of Manufacturers and is an Independent Director at Laboratory Corporation of America Holdings and GS1 AISBL. She received her undergraduate degree from Princeton University.

__________________________________________________________________________________

Timothy Schmid, MBA

Executive Vice President & Chairman Worldwide

Timothy has served as Executive Vice President and Chairman Worldwide since 2023. He joined Johnson & Johnson in 2023 and has held senior leadership roles across the healthcare and life sciences sectors prior to joining the company. Timothy earned his undergraduate degree from the University of Western Ontario and an MBA from Richmond University.

__________________________________________________________________________________

Find Johnson & Johnson's 10 Year Financial Statements below.

JNJ Financial Statements.xlsx

Download XLSX • 26KB